[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Municipal Hospital of Traditional Chinese Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":247},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,40,76,97,127,148,170,195,224],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100643433","phase-2-combination-of-cxd-and-restrictive-ketogenic-diet-against-masld-100643433",false,"NCT07639866","Combination of CXD and Restrictive Ketogenic Diet Against MASLD","Clinical Trial Study on the Combination of CXD and Restrictive Ketogenic Diet in Treating MASLD","Inclusion Criteria:\n\n* Age 18-50 years, regardless of gender\n* Meet the diagnostic criteria for MASLD\n* Meet the diagnostic criteria for dampness-heat accumulation syndrome in Traditional Chinese Medicine\n* Liver controlled attenuation parameter (CAP) ≥238 dB\u002Fm\n* Body mass index (BMI) ≥23 kg\u002Fm²\n* Possess adequate cognitive and comprehension abilities to understand the study content, its potential risks, and benefits;\n* Voluntarily participate in this study and personally sign the informed consent form\n\nExclusion Criteria:\n\n* Concurrent presence of other liver diseases that may lead to hepatic steatosis, specifically including drug-induced liver injury, alcoholic liver disease, autoimmune liver disease, viral hepatitis, and Wilson's disease\n* Concurrent severe dysfunction of major organs such as the heart, kidneys, or lungs, e.g., severe cardiac insufficiency (NYHA class III or higher), renal failure (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²), or acute exacerbation of chronic obstructive pulmonary disease\n* Subjects currently receiving treatment for MASLD\n* Concurrent presence of other severe systemic diseases, such as malignant tumors or active systemic lupus erythematosus\n* Known hypersensitivity or intolerance to any component of the study drug\n* Pregnant women, lactating women, or women of childbearing age who refuse effective contraceptive measures during the trial\n* Participation in other clinical trials within the past 3 months\n* Other circumstances deemed by the investigator unsuitable for participation in this study, such as severe mental disorders affecting compliance with the study","ALL","18 Years","50 Years",{"count":20,"type":21},135,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study employed a single-center, randomized, investigator-blind, three-group parallel, stepwise controlled clinical trial. A total of 135 subjects were randomly assigned to receive either a low-carbohydrate diet intervention, a restrictive ketogenic diet intervention, or a decoction preparation of the Tucha Lipid-Reducing Formula combined with a restrictive ketogenic diet. The trial duration consisted of 8 weeks of treatment followed by 8 weeks of follow-up. During the trial, participants adhered to dietary calorie control and moderate exercise as instructed in health education, self-reported their height, weight, waist-to-hip ratio, and other general parameters, and had weekly blood ketone level monitoring. Liver ultrasound, fasting blood glucose, lipid profiles, blood ketones, liver function tests, serum creatinine, urea nitrogen levels, and scores on the Traditional Chinese Medicine Syndrome Scale were measured before treatment initiation and at the end of the 8-week treatment period.",[27],"MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)","NOT_YET_RECRUITING","2026-06-06",{"date":31,"type":32},"2026-06-10","ACTUAL",{"date":34,"type":21},"2026-06-01",{"date":36,"type":21},"2027-02-01",{"name":38,"class":39},"Shanghai Municipal Hospital of Traditional Chinese Medicine","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":60,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100635247","phase-2-tiaoshen-anti-cancer-protocol-and-cbt-for-insomnia-and-survival-in-ovarian-cancer-100635247","NCT07550205","Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer","Tiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer: A Multicenter Randomized Trial","Inclusion Criteria:\n\n1. Patients aged 18 to 80 years (inclusive).\n2. Performance status (PS) score of 0-2.\n3. Histologically or cytologically confirmed primary epithelial ovarian carcinoma, with postoperative FIGO stage III-IV, and scheduled to receive postoperative standard first-line platinum-based chemotherapy.\n4. Having undergone ovarian cancer debulking surgery, in a stable condition at enrollment (no active infection, no severe hepatic or renal impairment, etc.), and planned for postoperative first-line platinum-based chemotherapy.\n5. Meeting the diagnostic criteria for ovarian cancer-related insomnia (difficulty initiating sleep, sleep maintenance disturbance \\[nocturnal awakening ≥2 times\\], early morning awakening with inability to return to sleep, occurring ≥3 times per week and lasting ≥1 month).\n6. Possess the ability to comprehend assessment scales and undergo Cognitive Behavioral Therapy for Insomnia (e.g., Mini-Mental State Examination score ≥24, or education level above primary school).\n7. Voluntarily sign the informed consent form, agree to receive the study treatment, and able to independently complete a sleep diary.\n\nExclusion Criteria:\n\n1. Previous systematic treatment with Cognitive Behavioral Therapy for Insomnia.\n2. History of chronic insomnia, depression, or other psychiatric disorders prior to ovarian cancer diagnosis, AND with a Patient Health Questionnaire-9 score ≥15 and a Generalized Anxiety Disorder-7 score ≥15, AND long-term use of hypnotic or psychotropic medications.\n3. Pregnant or lactating women.\n4. Comorbid severe primary diseases of the cardiovascular, cerebrovascular, pulmonary, hepatic, renal, or hematopoietic systems.\n5. Language barriers that would prevent completion of assessments or therapy.\n6. Comorbid autoimmune diseases, congenital or acquired immunodeficiency diseases, hematological diseases, or long-term use of corticosteroids or immunosuppressants.\n7. Active hepatitis B, active tuberculosis, or other severe or uncontrolled infectious diseases.\n8. History of chronic alcohol dependence.\n9. Concurrent other primary malignant tumors (except for cured non-melanoma skin cancer, carcinoma in situ of the cervix, etc.).\n10. Participation in any other clinical trial within 3 months prior to enrollment.\n11. Legally incompetent, or any medical or ethical reason that may hinder the continuation of the study.","FEMALE","80 Years",{"count":50,"type":21},360,[24,52],"PHASE3","Study Title: A Multicenter, Randomized Controlled Trial of Tiaoshen Anti-cancer Protocol Combined with Cognitive Behavioral Therapy for Insomnia in Improving Sleep and Survival in Ovarian Cancer Patients Purpose: This study aims to evaluate whether a combined therapy of traditional Chinese medicine (TCM) and modern psychotherapy can improve sleep and potentially extend survival for patients with ovarian cancer. Many patients experience severe, cancer-related insomnia, which lowers quality of life and may affect treatment outcomes.\n\nIntervention \\& Design: This is a randomized, double-blind, placebo-controlled trial conducted across multiple hospitals. Approximately 360 eligible patients with advanced ovarian cancer and significant insomnia will be enrolled.\n\nParticipants will be randomly assigned to one of two groups for the initial 18-week phase:\n\nExperimental Group: Receives the Tiaoshen Anti-cancer herbal formula granules plus standard Cognitive Behavioral Therapy for Insomnia (CBT-I).\n\nControl Group: Receives inactive placebo granules plus the same standard CBT-I. Neither the participants nor their treating doctors will know which granules are assigned during this phase. The primary goal is to compare the improvement in sleep quality between the two groups. Key secondary goals include assessing the therapy's impact on patients' anxiety, depression, overall quality of life, and the length of time before the cancer progresses (progression-free survival). All patients will receive standard-of-care chemotherapy.",[55,56,57,58,59],"Ovarian Neoplasms Malignant","Sleep Initiation and Maintenance Disorders","Medicine, Chinese Traditional","Chinese Herbal Medicine","Cognitive Behavioral Therapy",[61,62,63,64,65,66],"Ovarian Cancer","Cancer-Related Insomnia","Traditional Chinese Medicine","Cognitive Behavioral Therapy for Insomnia","Randomized Controlled Trial","Progression-Free Survival","2026-04-19",{"date":69,"type":32},"2026-04-24",{"date":71,"type":21},"2026-05-01",{"date":73,"type":21},"2029-09-30",{"name":38,"class":39},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100617579","phase-2-a-clinical-trial-of-longqi-jiangzhi-decoction-against-non-alcoholic-fatty-liver-disease-100617579","NCT07320456","A Clinical Trial of Longqi Jiangzhi Decoction Against Non-alcoholic Fatty Liver Disease","Effect of Longqi Jiangzhi Decoction on Non-alcoholic Fatty Liver Disease: a Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age 18-50 years, both genders eligible;\n2. Meets the diagnostic criteria for NAFLD;\n3. Meets the diagnostic criteria for Traditional Chinese Medicine Spleen Deficiency and Damp-Heat Syndrome;\n4. Has significant risk factors: CAP≥238dB\u002Fm, Body Mass Index (BMI) ≥23 kg\u002Fm²;\n5. Has not received any anti-NAFLD medication treatment in the past month;\n6. Normal major organ function, including heart, kidney, and liver functions, specifically: no significant abnormalities on electrocardiogram; normal serum creatinine and urea nitrogen; normal serum bilirubin and albumin levels;\n7. Has sufficient cognitive and understanding abilities to comprehend the study content and its potential risks and benefits;\n8. Voluntarily participates in the study and signs an informed consent form.\n\nExclusion Criteria:\n\n1. Has liver steatosis due to other definitive causes, such as alcoholic liver disease, drug-induced liver injury, viral hepatitis infections (e.g., hepatitis B, hepatitis C, etc.);\n2. Has other serious liver diseases, such as autoimmune liver diseases, primary biliary cholangitis, Wilson's disease, etc.;\n3. Has severe dysfunction of major organs such as the heart, kidneys, lungs, etc., such as severe heart failure (NYHA functional classification III or above), renal failure (glomerular filtration rate eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²), acute exacerbation of chronic obstructive pulmonary disease, etc.;\n4. Has other serious systemic diseases, such as malignant tumors, active systemic lupus erythematosus, etc.;\n5. Known allergy or intolerance to any component of the study medication;\n6. Has participated in another clinical trial within the last three months;\n7. Pregnant women, lactating women, or women of childbearing age who refuse to use effective contraception during the trial;\n8. Has severe mental illness or behavioral disorders that may affect adherence to the study protocol;\n9. Other conditions that the researcher considers unsuitable for participation in this study.",{"count":84,"type":21},80,[24],"The goal of this clinical trial is to learn if Longqi Jiangzhi decoction works to treat non-alcoholic fatty liver disease in adults. It will also learn about the safety of drug Longqi Jiangzhi decoction. Researchers will compare drug Longqi Jiangzhi decoction to a placebo (a look-alike substance that contains no drug) to see if drug Longqi Jiangzhi decoction works to treat non-alcoholic fatty liver disease. Participants will: Take drug Longqi Jiangzhi decoction or a placebo every day for eight weeks Keep a record of their symptoms and the degree of hepatic steatosis before and after the treatment.",[88],"Hepatic Steatosis","2025-12-21",{"date":91,"type":32},"2026-01-06",{"date":93,"type":21},"2025-12-29",{"date":95,"type":21},"2026-07-31",{"name":38,"class":39},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":75},"100593232","electroacupuncture-on-treating-cancer-related-depression-100593232","NCT07003763","Electroacupuncture on Treating Cancer-related Depression","The Effect and Safety of Electroacupuncture on Treating Cancer-related Depression: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Presence of depression attributed to cancer itself or cancer-related treatments, meeting the diagnostic criteria for depressive disorder（DSM-V).\n2. Age between 18 and 75 years, regardless of sex.\n3. Hamilton Depression Rating Scale-17 (HDRS-17) total score \\>17 at baseline.\n4. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2.\n5. No previous exposure to acupuncture treatment.\n6. Ability to understand the study procedures and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Planned to undergo surgery, chemotherapy, radiotherapy, immunotherapy, or other active cancer-related treatments during the study period.\n2. History of major depressive episodes prior to cancer diagnosis.\n3. Pain Rating Index (PRI) score ≥4 due to cancer-related pain.\n4. Estimated life expectancy of 12 months or less.\n5. Presence of severe ulcers, abscesses, or active skin infections at or near the acupuncture sites.\n6. Clinically significant dysfunction of major organs, including severe cardiac, cerebral, hepatic, renal impairment; decompensated pulmonary disease; or other serious systemic illnesses.\n7. Pregnant or breastfeeding women.\n8. Participation in another clinical trial within the past 30 days.\n9. Patients with a cardiac pacemaker or other implanted electronic medical devices.","75 Years",{"count":106,"type":21},86,[108],"NA","Cancer-related depression (CRD) is a common psychological condition among cancer patients during diagnosis, treatment, and recovery, and is associated with reduced quality of life, impaired immune function, and poorer clinical outcomes. As cancer incidence and mortality continue to rise in China, the psychological burden on patients is receiving increasing attention. Electroacupuncture (EA) has shown potential in treating various types of depression and related somatic symptoms, but evidence regarding its efficacy, safety, and long-term effects in CRD remains limited. This randomized controlled trial aims to evaluate the short- and long-term efficacy and safety of EA for CRD, with the goal of providing evidence to support effective and optimized treatment strategies.",[111,112],"Depression","Cancer",[114,115,116,117],"Electroacupuncture","cancer","depression","randomized controlled trial","RECRUITING","2025-12-16",{"date":121,"type":32},"2025-12-23",{"date":123,"type":32},"2025-07-01",{"date":125,"type":21},"2027-07-01",{"name":38,"class":39},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100596829","clinical-evaluation-of-the-tiaoshen-anti-cancer-regimen-in-treating-psycho-neurological-symptom-cluster-in-ovarian-cancer-100596829","NCT07050563","Clinical Evaluation of the Tiaoshen Anti-Cancer Regimen in Treating Psycho-Neurological Symptom Cluster in Ovarian Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed primary epithelial ovarian cancer\n* Meet diagnostic criteria for chronic insomnia defined by the Sleep Disorders Group of the Neurology Branch of the Chinese Medical Association: Pittsburgh Sleep Quality Index (PSQI) total score \\>8 Piper Fatigue Scale total score \\>4 and Patient Health Questionnaire-9 (PHQ-9) total score \\>5\n* Moderate-to-severe symptom severity (average score ≥4 on the MD Anderson Symptom Inventory for Ovarian Cancer \\[MDASI-OC\\] subscale assessing sleep disturbance-fatigue-distress-sadness)\n* Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score 0-2;\n* Age 18-70 years\n* Meeting TCM diagnostic criteria for spleen-kidney yang deficiency syndrome;\n* Expected survival \\>1 year\n* Signed informed consent form with voluntary acceptance of the treatment protocol and ability to independently complete sleep diaries\n\nExclusion Criteria:\n\n* Patients scheduled to undergo radiotherapy within the next 4 treatment cycles\n* Comorbid severe primary diseases of the heart, brain, liver, kidney, or hematopoietic system, including hepatic dysfunction (AST\u002FALT \\>1.5 times the upper limit of normal \\[ULN\\]) or renal impairment (serum creatinine \\[Cr\\] \\>1.2 times ULN)\n* Pregnant or lactating women, individuals with psychiatric disorders (e.g., schizophrenia, bipolar disorder, mania, depression, anxiety disorders, phobias), intellectual\u002Flanguage impairments, or other mental health conditions;\n* Scores ≥15 on the Patient Health Questionnaire (PHQ-9) for depression or ≥15 on the Generalized Anxiety Disorder-7 (GAD-7) at screening\n* Pre-existing chronic insomnia or depression diagnosed prior to ovarian cancer\n* Comorbid autoimmune diseases, hematologic disorders, or long-term use of corticosteroids\u002Fimmunosuppressants\n* History of other primary malignancies\n* Participation in other clinical trials within 3 months\n* HIV-positive status, congenital\u002Facquired immunodeficiency disorders, or history of organ transplantation (including autologous bone marrow or peripheral stem cell transplantation)\n* Legally incapacitated individuals, or cases with medical\u002Fethical contraindications to study continuation\n* Active hepatitis B, active tuberculosis, or evidence of severe\u002Funcontrolled systemic inflammatory conditions (e.g., unstable respiratory, cardiovascular, hepatic, or renal diseases)\n* Patients with diabetes","70 Years",{"count":135,"type":21},316,[108],"The academic community generally believes that cancer symptom clusters (CSCs) are not independent diseases, but a group of symptoms that accompany cancer patients. Based on etiology, they can be classified into CSCs related to tumor progression, CSCs related to cancer treatment, or a combination of both. According to symptom manifestations, they can be divided into psychological symptom CSCs, somatic symptom CSCs, and CSCs with coexisting psychological and somatic symptoms. CSCs are universally present during the progression or treatment of cancer. Traditional Chinese medicine (TCM) can leverage its unique characteristics in the intervention of symptom clusters and symptom management. This study is planned to conduct a high-level, prospective, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a TCM regimen for cancer symptom clusters (CSCs), and to simultaneously analyze the characteristics of the population that may benefit most from TCM treatment for CSCs.",[112,139],"Cancer Symptom Clusters","2025-09-23",{"date":142,"type":32},"2025-09-29",{"date":144,"type":21},"2025-10-06",{"date":146,"type":21},"2028-11-30",{"name":38,"class":39},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":154,"targetDuration":156,"studyType":157,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100596795","a-prospective-multi-center-real-world-study-of-ciwujia-capsules-in-the-treatment-of-cancer-related-insomnia-100596795","NCT07050121","A Prospective Multi-Center Real-World Study of Ciwujia Capsules in the Treatment of Cancer-Related Insomnia","Inclusion Criteria:\n\n1. Age ≥18 and ≤75 years.\n2. Histologically and\u002For cytologically confirmed diagnosis of malignancy. 3.Meet the diagnostic criteria for insomnia disorder per the Chinese Guidelines for Diagnosis and Treatment of Insomnia in Adults (2023) with one of the following conditions: 1）Directly cancer-related insomnia: Insomnia symptoms (e.g. difficulty falling asleep sleep maintenance difficulties early awakening) directly attributable to cancer-associated factors: ① Tumor-related factors: Pain cachexia dyspnea cough pruritus tumor compression symptoms etc. ② Cancer treatment-related factors: Chemotherapy-induced nausea\u002Fvomiting post-radiation mucositis surgical trauma etc. ③ Cancer-associated complications: Anemia infections metabolic disturbances etc. 2）Indirectly cancer-related insomnia: Insomnia directly caused by psychological stress reactions to cancer diagnosis or disease progression such as fear\u002Fanxiety about disease progression concerns about treatment side effects financial burden or psychosocial factors (e.g. insufficient family support).\n\n4.Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3. 5.Voluntarily participate and provide written informed consent.\n\nExclusion Criteria:\n\n1. History of allergy to any component of the investigational product.\n2. Liver dysfunction with ALT\u002FAST levels exceeding 1.5 times the upper limit of normal (ULN).\n3. Severe psychiatric disorders or emotional disturbances within the past year (e.g. anxiety depression suicidal tendencies or suicide attempts) requiring long-term use of CNS depressants or stimulants.\n4. Women who are pregnant breastfeeding or of childbearing potential unwilling to use effective contraception during the study.\n5. Insomnia secondary to uncontrolled severe cancer-related pain. 6.Participation in another clinical drug trial within the past month.",{"count":155,"type":21},3000,"56 Days","OBSERVATIONAL","Cancer poses a severe threat to human physical and mental health as well as survival. High diagnostic rates of cancer and various treatments can significantly impact patients' sleep quality, leading to diverse sleep disorders. Cancer-related insomnia (CRI) is a prevalent sleep disturbance among cancer patients, potentially associated with the tumor itself, treatment modalities (such as surgery, chemotherapy, radiotherapy), psychological status, pain, fatigue, and other symptoms. Although reported incidence rates vary across studies, CRI is consistently high and severely compromises patients' quality of life. Core symptoms include difficulty falling asleep, sleep maintenance difficulties, and early morning awakening, which contribute to daytime fatigue, impaired concentration and memory, ultimately detrimentally affecting patients' health and quality of life. The pathogenesis of CRI is complex, potentially involving multiple factors including the tumor's direct effects, treatment side effects, psychological distress, pain, and fatigue.\n\nThe primary component of Ciwujia capsules (containing Eleutherococcus senticosus extract) is Ciwujia extract. To clarify the clinical efficacy of Ciwujia capsules for cancer-related insomnia in real-world clinical settings, this study will employ a multicenter, prospective, open-label, real-world research design. It is projected to involve 30-50 centers over an approximate 3-year trial period, with a planned enrollment of 3,000 subjects. Changes in sleep-related indicators before and after treatment will serve as the primary endpoint observation metrics. The study aims to investigate the clinical efficacy and safety profile of Ciwujia capsules in treating insomnia disorders in cancer patients, thereby providing robust evidence for identifying effective Chinese herbal medicine therapies for sedation and sleep promotion.",[112,160,161],"Insomnia","Cancer Related Insomnia","2025-07-06",{"date":164,"type":32},"2025-07-08",{"date":166,"type":21},"2025-07-25",{"date":168,"type":21},"2028-12-31",{"name":38,"class":39},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":75},"100540397","effect-of-acupoint-thread-embedding-on-obesity-100540397","NCT06316310","Effect of Acupoint Thread Embedding on Obesity","The Effect and Safety of Acupoint Thread Embedding on Over-weight and Obesity Treatment : A Randomized, Single-Blind, Sham- Controlled Study","Inclusion Criteria:\n\n* Females aged 18\\~45 years old;\n* BMI≥24.0 kg\u002Fm2；\n* WC≥80cm ; recommended BMI and WC threshold value to define overweight in China;\n* Stable weight change (increase or decrease of ≤4 kg) within 3 months prior to the start of the test;\n* Agree to participate in the trial and sign a written informed consent form;\n\nExclusion Criteria:\n\n* Secondary obesity caused by drugs, or neuro-endocrine-metabolic disorders (such as thalamic disease, hypopituitarism, etc.);\n* History of bariatric surgery (gastric reduction, liposuction, etc.);\n* Are taking medications that may affect the results of the trial (weight):\n* Severe ulcers, abscesses, skin infections, etc. at the acupuncture site;\n* Severe heart, brain, lung, liver and kidney insufficiency, hematopoietic system disease or other serious diseases;\n* Participated in other clinical medical trial studies in the past 1 month;\n* History of acupoint thread embedding in the past 6 months;\n* Alcoholism, drug abuse, or smoking (change in smoking habits within the past 2 months or a plan to quit smoking during the study period);\n* Pregnant and lactating women.","45 Years",{"count":179,"type":21},132,[108],"The investigators describe a protocol for a randomized controlled trial to find out the effect and safety of acupoint thread embedding on losing weight in obese patients.",[183],"Obesity",[185,186,183,65],"Acupoint Thread Embedding","Sham Acupoint Thread Embedding","2024-12-06",{"date":189,"type":32},"2024-12-11",{"date":191,"type":32},"2024-03-15",{"date":193,"type":21},"2026-12-31",{"name":38,"class":39},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":211,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":75},"100550060","lcmd-for-type-2-diabetes-remission-evaluation-of-effectiveness-and-exploration-of-individual-differences-100550060","NCT06442150","LCMD for Type 2 Diabetes Remission: Evaluation of Effectiveness and Exploration of Individual Differences","Low-Calorie Medicinal Diet for Type 2 Diabetes Remission: Evaluation of Effectiveness and Exploration of Individual Differences","LCMD","Inclusion Criteria:\n\n* Physician-diagnosed T2DM\n* The history of T2DM less than 6 years\n* Most recent HbA1c higher than 6.5%\n* Body mass index: 24-45 kg\u002Fm2\n* Fasting C-p ≥1.1 ng\u002Fml\n* Inability to provide informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes, type 2 diabetes currently treated with insulin, or HbA1c ≥12%\n* Cardiovascular events within 6 months before trial\n* Current use of anti-obesity medications, eating disorders, dieting behaviors, or weight loss \\>5 kg within 6 months before trial\n* Chronic kidney disease stage 3b or above (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²)\n* Any condition causing fluid overload, such as heart failure or liver cirrhosis\n* Previously diagnosed psychiatric disorders (e.g., schizophrenia, post-traumatic stress disorder, obsessive-compulsive disorder), uncontrolled depression, or epilepsy\n* Severe arthritis or active gout\n* Active gallstone disease or known as asymptomatic gallstones\n* Concurrent enrollment in another clinical trial\n* Pregnancy, lactation, or planned conception during the study\n* Substance abuse\n* Known malignancy\n* Comorbidities increasing dietary intervention risk (e.g., biliary disorders)\n* Long-term use of antibiotics, corticosteroids, NSAIDs, or PPIs\n* Chronic gastrointestinal disorders affecting gut microbiota (e.g., ulcerative colitis)\n* Severe hepatic impairment (ALT \\>2.5× ULN)\n* Inability to provide informed consent","60 Years",{"count":205,"type":21},170,[108],"Type 2 diabetes (T2DM) has become a major public health problem. Achieving remission (HbA1c\\\u003C6.5% without glucose-lowering medications) has recently become a new treatment goal. Low-calorie diets effectively induce remission, but adverse effects like fatigue, appetite, and constipation hinder success. Integrating traditional Chinese medicine (TCM) herbs into a low-calorie diet may alleviate adverse effects and improve remission rates.\n\nThis project investigates the efficacy of a Low-Calorie Medicine Diet (LCMD) in achieving T2DM remission among overweight\u002Fobese individuals through a randomized controlled trial. The investigators will explore individual differences in remission and elucidate the underlying biological mechanisms, focusing on the brain-gut-microbiota axis. By integrating nutrition and TCM dietetics, this project provides a novel, evidence-based approach to managing T2DM in Chinese populations.",[209,210],"Type 2 Diabetes Mellitus in Obese","Type 2 Diabetes",[212,213,214,215],"Remission of type 2 diabetes","Low Calorie Diet","Medicined Diet","Brain-Gut-Microbiome axis","2024-05-29",{"date":218,"type":32},"2024-06-04",{"date":220,"type":21},"2024-06-01",{"date":222,"type":21},"2027-11-30",{"name":38,"class":39},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":246,"locationsCount":75},"100457476","effect-of-electroacupuncture-on-obesity-100457476","NCT05237089","Effect of Electroacupuncture on Obesity","Effects of Electroacupuncture on Weight Loss in Obese Patients With Prediabetes: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Male or female participants aged 18-65;\n2. Participant whose BMI is ≥24.0 kg\u002Fm2;\n3. Participants whose HbA1c measurement of 5.7-6.4% both inclusive, or fasting plasma glucose measurement ≥ 6.1 mmol\u002Fliter and \\\u003C7.0 mmol\u002Fliter, or 2-hour plasma glucose measurement post-challenge (oral glucose tolerance test) ≥7.8 mmol\u002Fliter and \\\u003C11.1 mmol\u002Fliter;\n4. Participants with stable weight within 3 months before the start of the trial, fluctuated within 4 kg;\n5. Participants who voluntarily agree with the investigation and sign a written informed consent form for the clinical trial.\n\nExclusion Criteria:\n\n1. Patients with secondary obesity caused by drugs or neuro-endocrine-metabolic disorders (such as hypothalamic disease and hypopituitarism);\n2. Patients who have been diagnosed with type I or type II diabetes;\n3. Patients who are taking medication which cause clinically significant weight gain or loss;\n4. Patients whose Hamilton 17-item Depression Scale (HAMD-17) score \\>18 or have a history of other severe psychiatric disorders;\n5. Patients with severe ulcer, abscess and skin infection at the local acupuncture area;\n6. Patients with severe diseases of multiple organs, such as heart, brain, lungs, liver, kidneys, hematopoietic system or other serious diseases;\n7. Participants who have joined in other clinical trials or studies within the past 1 month;\n8. Pregnant or lactating women.","65 Years",{"count":233,"type":21},256,[108],"The investigators describe a protocol for a randomized controlled trial to find out the effect and safety of electroacupuncture on losing weight in obese patients with prediabetes.",[183],[114,183,238,239,65],"Prediabetes","Sham acupuncture","2022-11-08",{"date":242,"type":32},"2022-11-10",{"date":244,"type":32},"2022-09-01",{"date":193,"type":21},{"name":38,"class":39},""]